Axesor's assessment of Zeltia's impact on the U.S. approval rating of Yondelis commercialization

27th October of 2015

Rating agency Axesor announces that it maintains Zeltia's rating in BB- with a stable trend, following approval by the American Food and Drug Administration (FDA) so that Janssen Biotech, partner of Pharma Mar (a subsidiary of Zeltia), can market the antitumor drug Yondelis (trabectidine) in the Us.